Trial reportTranslational psychiatry2017
The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback.
Trial report in Translational psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 46 citations in OpenAlex.
- Effects of estrogen and progesterone on neuroactive steroids and cytokines in patients with suicidality.Psychoneuroendocrinology · 2023Trial
- A Genome-Wide Association Study of Premenstrual Symptoms in Two Nordic Populations.Biological psychiatry global open science · 2026Article
- Molecular Mechanisms of Menstrual Cycle-Related Suicide Risk: A Selective Review of Promising Candidate Systems.Biological psychiatry · 2026Review
- Job Stress, Psychological Distress, and Menstruation-Related Symptoms in Female Workers: A Cross-Sectional Study.BJOG : an international journal of obstetrics and gynaecology · 2025Article
- Biomarkers of reproductive psychiatric disorders.The British journal of psychiatry : the journal of mental science · 2025Review
- Antioxidant and ameliorative effects of selected Nigerian plants on hormonal imbalance associated with dysmenorrhea in albino rats.Frontiers in nutrition · 2025Article
- Using estrogen and progesterone to treat premenstrual dysphoric disorder, postnatal depression and menopausal depression.Frontiers in pharmacology · 2025Review
- Neuroactive steroid hormone trajectories across the menstrual cycle in premenstrual dysphoric disorder (PMDD): the PHASE study.Molecular psychiatry · 2024Article
- Early Life Trauma, Emotion Dysregulation and Hormonal Sensitivity Across Female Reproductive Life Events.Current psychiatry reports · 2024Review
- GABAergic neuroactive steroid response to sertraline in premenstrual dysphoric disorder.Psychoneuroendocrinology · 2024Article
- Pharmacokinetics in Pharmacometabolomics: Towards Personalized Medication.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Towards understanding the biology of premenstrual dysphoric disorder: From genes to GABA.Neuroscience and biobehavioral reviews · 2023Review
- Role of estrogen in the regulation of central and peripheral energy homeostasis: from a menopausal perspective.Therapeutic advances in endocrinology and metabolism · 2023Review
- Role of allopregnanolone-mediated γ-aminobutyric acid A receptor sensitivity in the pathogenesis of premenstrual dysphoric disorder: Toward precise targets for translational medicine and drug development.Frontiers in psychiatry · 2023Review
- Reduced Dehydroepiandrosterone-Sulfate Levels in the Mid-Luteal Subphase of the Menstrual Cycle: Implications to Women's Health Research.Metabolites · 2022Article
- Affective Risk Associated With Menstrual Cycle Symptom Change.Frontiers in global women's health · 2022Article
- Major depressive symptoms in breast cancer patients with ovarian function suppression: a cross-sectional study comparing ovarian ablation and gonadotropin-releasing hormone agonists.BMC psychiatry · 2021Article
- Effects of exogenous melatonin on sleep and circadian rhythms in women with premenstrual dysphoric disorder.Sleep · 2021Article
- Response to sertraline is associated with reduction in anxiety-potentiated startle in premenstrual dysphoric disorder.Psychopharmacology · 2021Article
- The 5α-reductase inhibitor finasteride reduces opioid self-administration in animal models of opioid use disorder.The Journal of clinical investigation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
Abstract
Clinical evidence suggests that symptoms in premenstrual dysphoric disorder (PMDD) reflect abnormal responsivity to ovarian steroids. This differential steroid sensitivity could be underpinned by abnormal processing of the steroid signal. We used a pharmacometabolomics approach in women with prospectively confirmed PMDD (n=15) and controls without menstrual cycle-related affective symptoms (n=15). All were medication-free with normal menstrual cycle lengths. Notably, women with PMDD were required to show hormone sensitivity in an ovarian suppression protocol. Ovarian suppression was induced for 6 months with gonadotropin-releasing hormone (GnRH)-agonist (Lupron); after 3 months all were randomized to 4 weeks of estradiol (E2) or progesterone (P4). After a 2-week washout, a crossover was performed. Liquid chromatography/tandem mass spectrometry measured 49 steroid metabolites in serum. Values were excluded if >40% were below the limit of detectability (n=21). Analyses were performed with Wilcoxon rank-sum tests using false-discovery rate (q<0.2) for multiple comparisons. PMDD and controls had similar basal levels of metabolites during Lupron and P4-derived neurosteroids during Lupron or E2/P4 conditions. Both groups had significant increases in several steroid metabolites compared with the Lupron alone condition after treatment with E2 (that is, estrone-SO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.